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ABSTRACT: In this work cannabidiol (CBD) was investigated as
a possible drug against the cytotoxicity of Aβ(31−35) and Aβ(25−
35) peptides with the help of atomistic molecular dynamics (MD)
and well-tempered metadynamics simulations. Four interrelated
mechanisms of possible actions of CBD are proposed from our
computations. This implies that one mechanism can be a cause or/
and a consequence of another. CBD is able to decrease the
aggregation of peptides at certain concentrations of compounds in
water. This particular action is more prominent for Aβ(25−35),
since originally Aβ(31−35) did not exhibit aggregation properties
in aqueous solutions. Interactions of CBD with the peptides affect
secondary structures of the latter ones. Clusters of CBD are seen as
possible adsorbents of Aβ(31−35) and Aβ(25−35) since peptides are tending to aggregate around them. And last but not least,
CBD exhibits binding to MET35. All four mechanisms of actions can possibly inhibit the Aβ-cytotoxicity as discussed in this paper.
Moreover, the amount of water also played a role in peptide clustering: with a growing concentration of peptides in water without a
drug, the aggregation of both Aβ(31−35) and Aβ(25−35) increased. The number of hydrogen bonds between peptides and water
was significantly higher for simulations with Aβ(25−35) at the higher concentration of peptides, while for Aβ(31−35) that
difference was rather insignificant. The presence of CBD did not substantially affect the number of hydrogen bonds in the simulated
systems.
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■ INTRODUCTION
Positive pharmacological properties of cannabis have been
known for more than one century.1−3 Historically different
types of cannabis plants were successfully used for treating
tetanus,2,4 various types of pain,5,6 rheumatism,7 cholera,1,8 etc.
Later compounds extracted from cannabis plants such as trans-
Δ9-tetrahydrocannabinol (THC-9), cannabigerol, and canna-
bidiol (CBD) have shown a good potential in treating such
diseases as Alzheimer’s,9 Parkinson’s,10,11 autism,12 cholitis,13
cancer,14,15 post Ebola syndrome,16 and many others.
However, this very long history of successful applications of
cannabis plants and their compounds did not help in disclosing
the exact mechanisms of their actions.17−20
Nowadays the most commercially trending component of
cannabis is CBD, since its psychoactivity is not the same as of
THC-9.21,22 Moreover, due to the yearly increase of cases of
neurodegenerative diseases,23−25 CBD becomes a very
attractive drug because it has already shown the great potential
against them in various experimental studies.26−30 For
instance, G. Esposito et al.31 showed on rat primary astroglial
cultures that CBD could reduce the inflammation which was
Aβ-induced. R. Libro et al.32 discovered that CBD was
involved in the prevention of the expression of proteins
potentially involved in tau phosphorylation and Aβ-peptide
production. Long-term treatment of transgenic Alzheimer’s
disease mice with CBD prevented the development of social
recognition memory deficits according to D. Cheng et al.33
Thus, CBD can act in many different ways against
neurodegenerative diseases: it can prevent the production of
Aβ peptides, and it can probably act on cell membranes,
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peptide secondary structures, the ability of peptides to
aggregate, etc.30,31 In this work the accent is on the amyloid
hypothesis, which says that the development of Alzheimer’s
and Parkinson’s diseases happens due to the aggregation of Aβ
peptides in an extracellular space.34−37 Such aggregates build
plaques on cell membranes which cause apoptosis (cell’s
death) later.
There were different lengths of peptides found in the human
brain affected by Alzheimer’s and Parkinson’s diseases.38,39
Most of them belonged to the sequence Aβ(1−43), but they
were not equally cytotoxic.40 The importance of different
amino acid residues in the sequence and the role of their
positions in peptides on cytotoxicity have been investigated by
many research groups. For example, Aβ(25−35) (see Figure
1a) is considered as a more toxic part of the sequence than
others.41−43 This part is known to aggregate within hours.44 It
is physiologically present in elderly people,45 and it retains the
toxicity of the full length of the peptide Aβ(1−42).38
Another interesting part of the sequence is Aβ(31−35) (see
Figure 1a). It is known to induce cell apoptosis in isolated rat
brain mitochondria46 and in cultured cortical neurons of
newborn mice.47 In comparison with Aβ(25−35), Aβ(31−35)
was acting differently in inducing neurotoxicity of PC12 cells.48
According to F. Misiti et al.,48 Aβ(31−35) was acting via an
apoptotic cell death pathway, embracing caspase activation and
DNA fragmentation. Aβ(25−35) was inducing neurotoxicity
by adherent cell count without associating with any
biochemical features of apoptosis.48 Moreover, in the same
study it was noted that the C-terminus was involved in toxicity
mechanisms of both peptides but in different ways.
The short lengths of these peptides together with their
similarities in terms of sequences and their different ways of
inducing the cytotoxicity make them attractive candidates
together with CBD (Figure 1b) for theoretical studies using
classical atomistic MD and well-tempered metadynamics
simulations, particularly, because such studies have not been
conducted for mixtures of these molecules earlier. CBD has
been studied in silico only with Aβ(1−42), but those studies
were a combination of molecular docking and quantum
chemical calculations employing density functional theory.49 S.
Das et al.49 compared neuroprotective properties of
poyphenolic ligands and discovered that they could inhibit
the aggregation of Aβ(1−42). Other computational works
Figure 1. Molecules used in simulations: (a) the whole primary structure of the Aβ(1−43) peptide with denoted sequences of Aβ(25−35) (cyan
circles) and Aβ(31−35) (magenta rectangle) peptides; (b) CBD molecule.
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involving CBD were performed with other proteins, CBD
receptors, and lipids.50−53
There are not so many works with Aβ(31−35) or Aβ(25−
35) investigated by atomistic MD simulations. Only a few
studies have been conducted on Aβ(25−35), and surprisingly,
not even a single work has been carried out with the short
Aβ(31−35). H.-H. G. Tsai et al.54 performed replica exchange
molecular dynamics simulations where they investigated the
insertion of Aβ(25−35) and its mutants in a membrane.
However, both membranes and water models were implicit,
which does not explain the exact mechanisms of peptide−
membrane interactions. S.-W. Lee et al.55 investigated the
behavior of Aβ(25−35) in a trifluoroethanol solution in order
to understand the effect of the solvent on the conformational
distribution of the peptide. They found that trifluoroethanol
can promote the formation of α-helical structures.55 I.
Ermilova et al.56 studied the behavior of Aβ(25−35) in lipid
bilayers with and without cholesterol. They discovered that
MET35 in the C-terminus plays an important role in possible
hydrogen bond formations between lipid head-groups and
peptides. Moreover, according to their findings, Aβ(25−35)
exhibits aggregation properties on membranes loaded with
cholesterol, in agreement with latter experimental studies by T.
Murugova et al.57
The goal of this work is to investigate interactions between
short Aβ peptides (Aβ(31−35) and Aβ(25−35)) and CBD
and find their possible relations to cytotoxic properties of
peptides, using atomistic MD and well-tempered metady-
namics simulations. From atomistic MD simulations informa-
tion about peptide aggregation, their secondary structures and
associations with CBD molecules can be obtained. Further-
more, since in earlier experimental and computational studies
MET35 was pointed out as the amino acid residue that affected
the cytotoxicity most,56,58−60 it is of interest to see if CBD can
bind to it. Such a binding could imply a possible inhibition of
toxicity of peptides.
Additionally, the influence of the amount of water on
clustering of peptides is considered for the investigation, since
water is playing an important role in the protein
aggregation.61−63 Such a phenomenon can be studied by
increasing the amount of CBD and peptides at the same ratios
with a constant number of water molecules in simulations.
In the case of well-tempered metadynamics64−66 simulations
the idea is to investigate the aggregation between compounds
from a thermodynamic point of view, depending on the
amount of CBD molecules in the system. Such calculations
give an opportunity to select parameters of systems (collective
variables, CVs) and calculate the potential mean force (PMF)
of the system, depending on them, and integrate the resulting
PMF in binding free energies. As CVs it is convenient to select
distances between the molecular centers of mass. Choosing
different variables for various parts of the molecules would lead
to too many variables and constraints and, as a result, to a very
time-consuming simulation. If a value of the integral is negative
(ΔGbind < 0), then two molecules can bind; otherwise, the two
molecules are coexisting separately. Well-tempered metady-
namics is a time-consuming method; however, it is known for
not pushing the calculation to unattractive high free energy
regions.67 This advantage was the reason behind the choice of
the method in the current project. Thus, for Aβ(31−35) and
Aβ(25−35) it is feasible to calculate PMF and binding free
energies depending on distances between peptides and CBD
molecules, which could explain the peptide aggregation process
and its possible inhibition by CBD.
■ RESULTS AND DISCUSSION
Parametrization: Partial Atomic Charges for Canna-
bidiol. The computed final partial atomic charges are
demonstrated in Figure 2. Those charges were used for CBD
molecule in all simulations.
Radial Distribution Functions, Contact Maps, Hydro-
gen Bonds. Radial distribution functions (RDFs) are
characteristics of a system which provide information about
interactions and correlations between different components in
the system. For instance, RDFs between molecular center of
mass can answer the question if there is any affinity between
certain molecules.
Figure 3a presents RDFs between the molecular centers of
mass of Aβ(31−35) and CBD. In simulations with 6 molecules
the presence of CBD promotes aggregation of the peptides,
compared to the system containing no CBD. When 8
molecules are present, the situation is changing: the presence
of CBD is inhibiting the clustering of Aβ(31−35). These two
statements can even be confirmed by RDFs computed for
different time intervals (Figure S1 in Supporting Information):
the value of the function is higher and the first peak appears at
a closer distance in the end of the simulation for the system
with 6 CBD (Figure S1a,b in Supporting Information), while
in the case of 8 molecules an opposite trend is observed
(Figure S1c,d in Supporting Information). RDFs between
Aβ(31−35) and CBD show that there can be a strong
association between CBD molecules and peptides in the
system with 8 molecules, since the first peak appears at a
distance of less than 0.5 nm, as seen in Figure 3c. However, the
highest value of the RDF is observed at a distance of 0.9 nm
between the molecules. In the simulation with 6 molecules the
only peak is observed at a distance of 0.75 nm. Considering
that Aβ(31−35) has a length of around 1.35 nm and the length
of the CBD molecule is about 1.35 nm, one can conclude that
there can be strong associations between CBD and the
peptides in both systems.
In the case of Aβ(25−35) the inhibition of aggregation is
observed for systems with 6 molecules of each compound
when CBD is present in the simulation, while with 8 molecules
the promotion of clustering in the presence of CBD can be
seen in Figure 3b. Figure S2 in Supporting Information
confirms that with a lesser amount of molecules the inhibition
of aggregation of Aβ(25−35) is highly likely to occur.
Figure 2. CBD molecule with derived partial atomic charges. Here
black values are charges for carbon atoms, dark blue values are charges
for hydrogen atoms, and red values are charges for oxygen atoms.
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More details of the peptide aggregation can be seen on
contact maps. Figures S3−S10 in Supporting Information
demonstrate such contact maps for peptides taken after 3 time
intervals (150 ns, 200 ns, and 250 ns) during production runs
using the VMD software.68
For Aβ(31−35) less contacts (gray points) are observed in
the system with 6 peptides than in the system with 6 peptides
and 6 CBD molecules (Figures S3 and S4), while in
simulations with 8 molecules of peptides and peptides with
CBD the number of gray points is smaller in the system
containing the peptides and the drug (Figures S5 and S6).
Contact maps for systems containing 6 Aβ(25−35) show a
higher number of contacts when CBD is absent (Figures S7
and S8). A similar effect of the presence of CBD can be seen
even for the systems with 8 molecules: more gray points when
the drug is not in the system and less when it was added
(Figures S9 and S10).
Considering RDFs between peptides and CBD, Figure 3d
shows a strong affinity between the molecules in the system
with 8 CBD and 8 Aβ(25−35) and a weaker one in the similar
system with 6 molecules of each compound. However,
Aβ(25−35) has a double length of Aβ(31−35), which
means that it can explore a larger variety of conformations,
and therefore, the coordinates of the centers of mass and the
radius of gyration can fluctuate. For instance, from our of
knowledge of lengths of stretched peptides it follows that the
radius of gyration for Aβ(31−35) can be smaller than for
Aβ(25−35). Considering the full length of the peptide, one
can still conclude that there is an affinity between CBD and
Aβ(25−35) rather than an aversion. Figure S11 in Supporting
Information demonstrates the evolution of RDFs between
CBD and peptides in various time intervals, and Figures S12−
S19 show changes in radius of gyration for every peptide
during production runs.
Since CBD affects the aggregation of Aβ peptides,
information about which parts of the molecules are associating
would be useful for understanding how such interactions can
possibly affect the toxicity of Aβ(25−35) and Aβ(31−35).
RDFs between centers of mass of amino acid residues and
selected parts of CBD can answer this question. Figure 4
demonstrates such RDFs between the dihydroxyphenyl ring of
CBD and the different amino acid residues. In simulations with
Aβ(31−35) MET35 is the amino acid residue that associates
most with the ring in both simulations (Figure 4a,b): a small
peak is observed at a distance of 0.15−0.2 nm. Other amino
acid residues which can be found at a close distance to CBD
are GLY33 in the system with 6 molecules and ILE31 in the
system with 8 molecules.
In simulations with Aβ(25−35) MET35 associates with CBD
in both systems with 6 and 8 molecules of each compound (see
Figure 4c,d). In the system with 8 molecules ILE32 is the
second amino acid residue that can bind to CBD. Two other
Figure 3. RDFs between molecular center of mass, computed over 250 ns: (a) Aβ(31−35) and Aβ(31−35); (b) Aβ(25−35) and Aβ(25−35); (c)
Aβ(31−35) and CBD; (d) Aβ(25−35) and CBD. The visualization is the following: purple ribbons are Aβ(25−35), blue ribbons are Aβ(31−35),
and green molecules are CBD. The sizes of molecules were rescaled for the purpose of the schematic visualization.
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amino acid residues with values of RDFs above 1 at short
distances below 0.2 nm are GLY33 and GLY29 but only in the
simulation with 6 molecules. In the system with 8 molecules
there are no significant peaks at short distances for the other
amino acid residues. This can happen due to conformational
rearrangements in Aβ(25−35) in a more crowded environ-
ment and with the lesser amount of water.
The fact that CBD can bind to MET35, which is in C-
terminus of both Aβ(31−35) and Aβ(25−35), can be
considered as one possible way of decreasing the cytotoxicity
of both peptides. For instance, F. Misiti et al.59 have used two
kinds of Aβ(31−35) in experiments with isolated mitochondria
from rat brain, where in one of the cases MET35 was oxidized
to methionine sulfoxide. They noted a reduction of toxic and
proapoptotic effects of Aβ(31−35) with modified MET35,
compared to the original one. M. E. Clementi et al.46 showed
that the substitution of MET35 by norleucine in Aβ(31−35)
and Aβ(25−35) inhibited the apoptotic effects of those
peptides in experiments with a clonal line of rat pheochromo-
cytoma. S. Gengler et al.44 have tested the ability to aggregate
using Aβ(25−35) in comparison with Aβ(35−25) (reverse
sequence with GLY in C-terminus). Their experiments showed
that Aβ(35−25) does not aggregate, in contrast to Aβ(25−
35). I. Ermilova et al.56 have simulated Aβ(25−35) in a
phospholipid bilayer environment and observed that MET25
binds strongest to the membrane. Thus, preventing the binding
of MET35 by using a drug binding to it could be one possible
solution for decreasing the cytotoxicity of Aβ(25−35) and
Aβ(31−35).
Interactions between other parts of the CBD molecules and
the amino acid residues did not result in high values of RDFs
at short distances (see Figures S20 and S21 in Supporting
Information), probably because those parts of the drug are
mainly hydrophobic and only the dihydroxyphenyl ring has
two hydroxyl groups that can participate in hydrogen bonding
between CBD and the peptides.
Nevertheless, the knowledge about the associations between
centers of mass of MET35 and the dihydroxyphenyl ring of
CBD does not tell whether there is a binding between atoms in
C-terminus or other atoms in MET35. In order to confirm the
possible binding between atoms of MET35 and the
dihydroxyphenyl ring, RDFs between selected pairs of atoms
Figure 4. RDFs between centers of mass of amino acid residues and a selected part of CBD molecule (the dihydroxyphenyl ring), computed over
250 ns: (a) 6 Aβ(31−35) and 6 CBD; (b) 8 Aβ(31−35) and 8 CBD; (c) 6 Aβ(25−35) and 6 CBD; (d) 8 Aβ(25−35) and 8 CBD. The
dihydroxyphenyl ring is shown in (a), where the gray color denotes hydrogens, carbons are in cyan color, and oxygens are red. Zoomed insets
demonstrate RDFs at short distances.
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were calculated (see Figures S22−S24 in Supporting
Information). Figure S22 demonstrates associations between
hydrogen atom in the dihydroxyphenyl ring and nitrogen atom
in MET35 (the red curve with peaks at 0.3 nm for all simulated
systems) which can be classified as a weak hydrogen bonding
interaction. The sulfur atom in MET35 shows the ability to
build strong and weak hydrogen bonds with hydrogens binding
to carbons as well as with hydroxyl hydrogens in the
dihydroxyphenyl ring of CBD (Figure S23). Moreover,
hydrogen atoms from the CH3-group of MET35 can form
weak hydrogen bonds with oxygens from dihydroxyphenyl ring
of the drug molecule (Figure S24).
Additionally, the simulated drug molecules can aggregate
with themselves. The CBD molecules demonstrated the
strongest association with themselves in systems containing
no peptides, while for systems with peptides the aggregation of
CBD was most pronounced when 8 molecules of the peptides
were present (Figure S25 in Supporting Information).
And last but not least, the role of the amount of water for
aggregation of Aβ peptides is of importance according to our
simulations. Considering only simulations without CBD, it was
found that both Aβ(31−35) and Aβ(25−35) cluster more
easily when their concentration in water is higher as seen in
Figure 3a,b by comparing the results for 6 and 8 molecules.
The addition of CBD changes the situation: Aβ(31−35)
aggregates most in the system with 6 molecules of CBD and
the peptide, while Aβ(25−35) shows a stronger association at
a higher amount of these molecules.
One reason for such a different behavior of peptides can be
their discrepancy in size, compared to the size of the CBD
molecule, which has a length similar to the length of Aβ(31−
35) but shorter than Aβ(25−35). The shortest peptide can
probably be separated by the drug molecules due to their
similarities in sizes, while for the long Aβ(25−35) the situation
may differ: due to its length, it has an ability to wrap around
the CBD molecule.
Another cause of such a diverse aggregation is the presence
of a hydrophilic region (25−28) in Aβ(25−35), which does
not exist in the shorter peptide. With an increasing amount of
both CBD and peptide in systems with Aβ(25−35) the
amount of the hydrophilic part is increasing as well (it means
that there will be more atoms able to participate in hydrogen
bonding interactions), while in the simulations with Aβ(31−
35) only hydrophobic regions are present. As it was earlier
observed by various research groups, for longer Aβ-peptides,
the stability of aggregates was dependent on the hydrophobic
interactions in the domain (29−42), which is partially present
in both peptides, as well as the existence of the β-turn
secondary structure in the hydrophilic region (25−28).69−73
This hydrophilic region is involved in hydrogen bonding
between peptides and water, which is engaging more water
molecules than in the case of 6 peptides (the number of water
molecules was the same in the simulated systems) and,
probably, be a cause for the differences in aggregation of
Aβ(25−35) compared to Aβ(31−35). Figures S26 and S27 of
Supporting Information show how the number of hydrogen
bonds between peptides and water depends on the water
content and the presence of CBD. For systems with Aβ(31−
35), both with and without CBD, the number of hydrogen
bonds is higher in simulations with 8 molecules than in
simulations with 6 (Figure S26). However, the differences
between the 4 systems are not substantial. In the case of
Aβ(25−35) the number of hydrogen bonds increases
substantially with increasing concentration of peptides (i.e.,
decreasing water concentration), and as for Aβ(31−35) the
number of hydrogen bonds does not depend on the presence
of CBD in the systems (Figure S27).
Secondary Structures of the Peptides. Protein
secondary structure is known to have an impact on the
function of the protein. Such a function can be not only vital
for the cell but even cytotoxic.74,75 Therefore, another way to
investigate the effect of CBD on Aβ peptides is to study how
the presence of the drug can affect the structures of Aβ(31−
35) and Aβ(25−35). This investigation was carried out with
the help of the VMD software.68
Figure S28 in Supporting Information demonstrates
secondary structures for each peptide in the simulation with
6 molecules of Aβ(31−35). Dominating structures are turn
and coil and quite few isolated β-bridges, and α- and 310-
helixes can be observed. When 6 molecules of CBD are present
in the system, the number of isolated β-bridges increases; no
helixes can be detected any longer, and extended conforma-
tions appear (Figure S29). In simulations with 8 peptides
containing no drugs dominating secondary structures are turn,
coil, and many isolated β-bridges, and extended conformations
can also be observed (Figure S30). In the presence of 8 CBD
molecules the number of isolated β-bridges and extended
conformations is lower, and instead turn and coil are the
dominating secondary structures (Figure S31).
Returning to the RDFs, it is now possible to see correlations
between the aggregation of Aβ(31−35) and its secondary
structures. When CBD was absent in the system with 6
peptides (most of the structures here were turn and coil), the
peptides were aggregating less than when CBD was present
(extended conformations and isolated β-bridges are present in
larger amounts in the latter case). Then in the case of 8
molecules of Aβ(31−35) the aggregation of peptides was more
pronounced when CBD was absent (extended conformations
and isolated β-bridges are present in larger amounts) and
substantially reduced in the system with the drug (most of the
structures here were turn and coil).
Secondary structures of 6 Aβ(25−35) without CBD in the
system can be seen in Figure S32 of Supporting Information.
Turn and coil are dominating structures, but a large number of
extended conformations, isolated β-bridges, and 310-helixes can
also be observed. The less represented structure is α-helix. In
the presence of 6 CBD molecules (Figure S33) the number of
extended conformations is smaller, as is the number of 310-
helixes. There are no α-helixes observed in any of the peptides.
Turn, coil, and isolated β-bridge are the dominating secondary
structures. In the system with 8 Aβ(25−35) without any CBD
(Figure S34) the most represented secondary structures are
extended conformation, turn, and coil, which can be seen in
every peptide. Isolated β-bridges and α-helixes can be observed
as well but in smaller amounts. With the addition of 8 CBD
molecules (Figure S35) to the system with 8 Aβ(25−35) the
number of extended conformations is decreasing and a lesser
amount of α-helixes is detected, but 310-helixes and isolated β-
bridges are getting more pronounced.
Then these results for Aβ(25−35) can be connected to the
results from the RDF analysis, since the aggregation and high
values of RDFs at shorter distances can be related to the
presence of certain peptide secondary structures in the
modeled systems. For instance, in simulations with 8
molecules, extended conformations can be detected in large
amounts (during the whole simulation time) in almost every
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single peptide, regardless if CBD is present or absent. In all
those simulations a high aggregation of Aβ(25−35) is
observed. In systems with 6 molecules a larger number of
extended conformations in different combinations with
isolated β-bridges appear when CBD is absent, while in the
presence of CBD these structures exist in smaller amounts. For
those simulations peptides were aggregating strongest in the
absence of the drug and much less in its presence. Thus, a high
number of extended conformations and β-bridges is correlated
with a stronger aggregation of Aβ(25−35).
Indeed, secondary structures in combinations with RDFs
give some idea about how the aggregation of Aβ peptides
occurs or, better to say, what conformations should be
dominant in order to observe such a phenomenon. Extended
conformations were seen in amyloid fibrils and precipitates in
experimental studies.76−79 The presence of β-turn structures in
the hydrophilic domain (25−28) and the hydrophobic domain
(29−35) was pointed out as the essential “conditions” for
stable aggregation of Aβ-peptides by C. J. Pike et al.69 and
many others.71−73 Thus, results from those experimental
studies seem to have some agreement with our findings.
Nevertheless, a discussion about how the secondary
structure may give a rise to pharmacological effects shall be
completed by taking a look at the systems’ screenshots. Figure
5 demonstrates screenshots of the final frames for systems
containing CBD and peptides. All images have something in
common: the drug molecules are clustered, and the peptides
surround these clusters. Considering the mechanisms of
actions of CBD, it would be reasonable to think about two
possible ways: the first one is a separation of peptides and the
second one is their ”adsorption” on the surface of CBD
clusters. Which of the mechanisms is the most effective against
cytotoxicity cannot be concluded from simulations, since any
toxic effect shall be evaluated on living neurons.
Potential Mean Force Profiles and Free Energies from
Well-Tempered Metadynamics. The resulting potential
mean force (PMF) profiles for all simulations with Aβ(31−35)
are shown in Figure 6. Since the length of a stretched peptide is
about 1.5 nm, distances longer than 1.8 nm were not
considered for the analysis. In Figure 6a it can be seen that
the area of the lowest energy is situated at a distance between
the peptides (CV1) of 0.5−0.8 nm and at a distance between
peptide-1 and CBD (CV2) of 0.3−0.7 nm. This implies that
two Aβ(31−35) can be situated close to each other regardless
of the presence of the CBD molecule. At the same time dark
areas of the same color but weaker intensity can be observed at
the same distance for CV1 but at a longer distance for CV2,
which means that two peptides can be located close to each
other even if 1 CBD molecule is further apart, but with a lower
probability. Figure 6b shows the profile for the simulation with
2 peptides and 2 CBD molecules. Two clear points of minima
can be determined here: one point for a distance between the
peptides of 0.4−0.6 nm and the same distance between one of
the peptides and one CBD molecule. Another point is for the
same distance between the peptides and a distance between
one of the peptides and one of the CBD molecules of 0.8−0.9
nm. Such an existence of 2 well distinguished minima indicates
that aggregation of two peptides is equally probable when 1
CBD molecule is situated at one of those defined distances.
When the CBD molecule is at the distance of 0.8−1.2 nm, two
dark areas with lower intensity can be observed when the
distances between the peptides are 0.7−0.8 nm and 1.4−1.5
nm, which means that peptides can be separated in the
presence of CBD molecules. Since a comparison of the free
energy maps shows that several points of minima at various
distances between the molecules can be observed at the
presence of 2 CBD molecules, it can be concluded that the
drug can inhibit aggregation.
However, regardless of these results, a final conclusion about
aggregation can be made only if the results are compared with
a simulation of a corresponding system containing no CBD.
Figure 6c demonstrates PMF profiles for 3 systems with
Aβ(31−35), including one without CBD (green line). Red and
blue profiles were obtained from an integration of the free-
energy maps computed for systems with 1 and 2 CBD
molecules, respectively. For the simulation without any drug
the curve looks rather flat after a distance of 0.45 nm,
compared to the two other curves. In the system with 1 CBD
molecule the peptides cluster more easily than in the
simulation with 2 CBD molecules. This implies that Aβ(31−
35) has a low tendency to aggregate even without CBD, but if
CBD is present in the system, then a higher amount is
favorable for separating the peptides.
Then the question arises about the affinity of CBD to
Aβ(31−35). Figure 6d presents integrated PMF profiles for
interactions between the peptide and CBD. It is clear that in
the system with 1 CBD molecule Aβ(31−35) has a stronger
affinity to the CBD molecule, while in the system with 2 CBD
molecules the global minimum is observed at a longer distance
between the peptide and CBD (at about 1.1 nm). This implies
that CBD prefers to be located relatively far away from
Aβ(31−35) when 2 CBD molecules are present. Thus, it is
Figure 5. Screenshots of the final simulation frame: (a) 6 Aβ(31−35)
and 6 CBD; (b) 6 Aβ(25−35) and 6 CBD; (c) 8 Aβ(31−35) and 8
CBD; (d) 8 Aβ(25−35) and 8 CBD. Here, green molecules are CBD,
purple ribbons are Aβ(25−35), and blue ribbons are Aβ(31−35).
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possible that the second CBD molecule could be involved in
the inhibition of peptide aggregation.
For the larger peptide Aβ(25−35) the situation with
aggregation is different, compared to Aβ(31−35). The
stretched Aβ(25−35) is much longer than Aβ(31−35)
(approximately 3 nm). Therefore, the distances considered
for calculations are a bit longer. Figure 7a demonstrates the
free energy map for the system containing 2 peptides and 1
CBD molecule. The global minima is located at a distance
between the peptides of 0.7−0.8 nm when the CBD molecule
is situated at about 0.2 nm from one of the peptides. At this
distance between the peptides and a distance between CBD
and one of the peptides of 1.7 nm a local minima can be
observed, which means that peptides can aggregate even if the
CBD molecule is relatively far away. A local minima with a
similar intensity can be seen even at a distance between the
peptides of 1.2 nm, when the distance between one of the
peptides and the CBD is about 1 nm. This implies that the
peptides can be separated when the CBD molecule is far away.
However, since the global minimum is at a distance that is
much smaller than half the length of the stretched peptide, one
can conclude that aggregation is more dominant in this
mixture, but barriers from bound to unbound states are not
big. In the simulation with 2 CBD molecules, aggregation does
not dominate anymore (Figure 7b). The barrier between
bound and unbound states is smaller than in the one-
dimensional simulation. This implies that less energy is needed
for separating the peptides. There are several areas with
Figure 6. PMF profiles for well-tempered metadynamics simulations with Aβ(31−35). (a) Simulation with 2 peptides and 1 CBD molecule. (b)
Simulation with 2 peptides and 2 CBD molecules. (c) Green curve is for one-dimensional simulation containing no CBD molecules. Red and blue
curves are integrated profiles for peptides from simulations containing 1 and 2 CBD molecules, respectively. (d) Red and blue curves are integrated
profiles for peptides and CBD molecules from simulations containing 1 and 2 CBD molecules, respectively. CV1 and CV2 are defined in Figure 9.
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minima in PMF. Those areas appear at different distances
between the peptides as well as between CBD and one of the
peptides. The free energy landscape appears more homoge-
neous and flat, compared to the one with a single molecule of
the drug.
From the PMF it can be concluded that aggregation of the
peptides does not dominate in the system. As in the previous
case of Aβ(31−35) it is reasonable to consider the system
without any CBD in order to understand if the drug can give
any ”benefits” in terms of inhibition of peptide aggregation.
Figure 7c demonstrates that without CBD Aβ(25−35)
aggregation is more probable since the global free energy
minimum is deeper and placed at a shorter distance of 0.5 nm,
compared to the systems with 1 and 2 CBD molecules.
Moreover, the curve for the system with 2 CBD is placed
higher than the curve for the system with 1 CBD, which
implies that the higher concentration of the drug inhibits the
aggregation better than the lower one. Nevertheless, Figure 7d
shows that there is a higher affinity of CBD to Aβ(25−35) in
the system with only one drug molecule, compared to the
system with two CBD molecules. This behavior is similar to
that observed for the systems with Aβ(31−35). Then we can
also speculate that the second CBD molecule plays a big role in
the inhibition of the peptide aggregation process.
Observing energetically favorable distances is a good
approach for understanding if molecules are binding to each
Figure 7. PMF profiles for well-tempered metadynamics simulations with Aβ(25−35). (a) Simulation with 2 peptides and 1 CBD molecule. (b)
Simulation with 2 peptides and 2 CBD molecules. (c) Green curve is for one-dimensional simulation containing no CBD molecules. Red and blue
curves are integrated profiles for peptides from simulations containing 1 and 2 CBD molecules, respectively. (d) Red and blue curves are integrated
profiles for peptides and CBD molecules from simulations containing 1 and 2 CBD molecules, respectively.
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other, but the final conclusion can be made only after an
integration of the PMF profiles. Table 1 presents results from
such calculations. Binding free energies were calculated




























Here kB is the Bolztmann constant, T is the temperature during
the simulation, β = 1/(kBT), z is the value of a CV, and w(z) is
the value of the PMF. The integral, denoted by the letter B,
stands for the bound state (when two molecules are close
enough to each other so that binding can occur), and the letter
U stands for the unbound state (when two molecules are far
away from each other and no binding between them can
happen).
In Table 1 values of binding free energies are shown. They
give insight into how likely two molecules are bound to each
other. In the system with only 2 Aβ(31−35) the binding free
energy is higher than in the systems with CBD. The positive
value of binding free energy implies that two molecules are
highly unlikely to bind. In the simulations with the drug the
two peptides have the lowest binding free energy when only 1
CBD is present in the system. At the same time this CBD
molecule has a higher affinity to a peptide than in the system
containing 2 CBD molecules. In the case of Aβ(25−35) the
lowest binding free energy between the peptides was observed
in simulations without any drug and the highest one was for
the system with 2 CBD molecules. This implies that at a higher
content of CBD Aβ(25−35) is less likely to aggregate. Peptide
and CBD have the lowest binding free energy in the system
with 1 drug molecule, while in the simulation with 2 CBD
molecules the value of free energy is positive, which implies
that the two molecules are unlikely to bind to each other.
These diverse aggregation properties of Aβ(31−35) and
Aβ(25−35) in aqueous mixtures without drugs were observed
in experiments by C. J. Pike et al.70 Moreover, according to
their earlier studies,69 the ability of Aβ(25−35) to build
aggregates is strongly related to the presence of both
hydrophilic (25−28) and hydrophobic (29−35) domains,
where the (25−28)-region of the sequence is “responsible” for
the stability of the aggregates due to its β-turn secondary
structure.71−73 However, in the presented free energy
calculations secondary structures were not taken into account
during calculations.
The information about the quality of sampling and
convergence of presented well-tempered metadynamics
simulations can be found in the section 2 of Supporting
Information.
Possible Mechanisms of Actions. The cytotoxicity of Aβ
peptides is a complex phenomenon that can depend on many
different factors such as their secondary structure, their
tendency to aggregate, their ability to bind, and even the
amount of water and other chemical compounds in living
organisms.
Aβ(31−35) and Aβ(25−35) are already known to differ in
aggregative properties and in neurotoxic mechanisms from
various experiments, regardless that they are sharing the same
part of the sequence (31−35).
Results from our MD simulations showed that there are 4
possible interrelated mechanisms of actions of CBD on the
investigated peptides (Figure 8). Therefore, it is important to
say that one mechanism can be the cause or/and the
consequence of another.
The first one is an inhibition of aggregation of the peptides
(Figure 8a). Aβ(25−35) exhibited different aggregation
properties comparing to Aβ(31−35) in mixtures containing
no drug, which was in agreement with experimental results.69,70
However, in the presence of the CBD molecules, depending on
their concentration in water, the peptides showed sundry
behavior. This shall give rise to future investigations of various
CBD:peptide:water ratios in order to find the optimal
concentration of the drug. Due to the big differences in results
from classical MD simulations, it would also be worth
considering possible nanotoxic effects of both CBD and
peptides.80,81
The second one is binding of the dihydroxyphenyl ring in
CBD to MET35 (Figure 8b). Since this amino acid residue has
been seen as a possible cause of cytotoxicity,46,48,59,60,82 CBD
can certainly be considered as a possible drug.
The third one is a CBD induced alteration of the secondary
structure of the Aβ peptides (Figure 8c). It was discovered in a
number of experimental studies that certain secondary
structures were dominating in the case of aggregation and
therefore seem to promote or to be required for stable
aggregation.69−73 Since a protein can “change” its function by a
change of its secondary structure, one can speculate that our
observation that CBD gives rise to lesser amounts of extended
Table 1. Free Energies
binding free energy (kJ/mol)
system Aβ ↔ Aβ Aβ ↔ CBD
2 Aβ(31−35) 0.332
2 Aβ(31−35) + 1 CBD −1.343 −1.050
2 Aβ(31−35) + 2 CBD −0.318 −0.453
2 Aβ(25−35) −12.911
2 Aβ(25−35) + 1 CBD −2.348 −6.302
2 Aβ(25−35) + 2 CBD −0.977 0.247
Figure 8. Illustration of possible mechanisms of actions of CBD on
Aβ peptides: (a) inhibition of peptide aggregation; (b) binding of the
dihydroxyphenyl ring to MET35 (the amino acid residue is accented
by an ellipse); (c) change of the secondary structure; (d) clustering of
CBD with adsorption of peptides around the clusters. Here colors are
the following: “blue” ribbons are Aβ(31−35), “purple” ribbons are
Aβ(25−35), and “green” molecule is CBD. Sizes of molecules were
rescaled for clarity.
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conformations in combinations with isolated β-bridges of the
peptides may be related to reduced toxicity and aggregation.
The fourth possible mechanism of action is the adsorption of
peptides on CBD clusters (Figure 8d). In MD simulations high
values of intermolecular RDFs were observed at shorter
distances in the presence of the CBD molecules, but the
screenshots showed that aggregates are built around the drug
clusters. Aβ(31−35) has a similar length as the CBD molecule,
while Aβ(25−35) has a double length of the drug. At a higher
concentration of both molecules the separation of the shortest
peptide can be observed due to the drug cluster in between,
while for Aβ(25−35) an aggregation of peptides on such a
cluster can appear as the aggregation of the peptides (since
their centers of mass are close to each other). Thus, if peptides
would associate with each other on such clusters, perhaps they
would not aggregate on membrane surfaces.
Additionally we can conclude that the amount of water has a
strong effect on the tendency of the peptides to aggregate in
the absence of CBD: both were aggregating more easily in
systems with 8 molecules than in simulations with 6. The
number of hydrogen bonds between water and peptide
molecules was higher in systems with Aβ(25−35) than with
Aβ(31−35). A growing concentration of peptides significantly
increases the number of hydrogen bonds for the longer
peptide, while in the case of the shorter one the number of
hydrogen bonds was not substantially affected by concen-
trations of peptides and water.
Well-tempered metadynamics simulations on a microsecond
time-scale provide information about the energetics of the
different molecular interactions, which in turn can partially
explain the observations made from the classical MD
simulations. Aβ(31−35) does not aggregate in the absence
of CBD. In the mixture with 1 CBD molecule it shows the
strongest tendency to aggregate. Also the affinity of Aβ(31−
35) toward CBD is higher than in the mixture with 2 CBD
molecules. The presence of the second CBD molecule affects
the energetics of the peptide−peptide and peptide−CBD
interactions by suppressing the aggregation of the peptides.
However, the cytotoxicity of Aβ(31−35) is not related to its
aggregation. As it was shown in several experimental
works,46,70 Aβ(31−35) did not aggregate in aqueous solutions
and its toxicity was not correlated with its ability to aggregate.
The aggregation of Aβ(25−35) is gradually inhibited at
higher amounts of CBD. The affinity of Aβ(25−35) toward the
selected CBD molecule is lower at the highest amount of the
drug in the system. Since the toxicity of Aβ(25−35) is strongly
related to its aggregation, the inhibition of this process by CBD
can probably suppress the cytotoxicity of Aβ(25−35).
■ CONCLUSIONS
In this work, we have investigated possible mechanisms of
actions of CBD against cytotoxicity of Aβ(31−35) and
Aβ(25−35) applying advanced in silico methods such as
classical MD and well-tempered metadynamics simulations.
We propose four possible interrelated mechanisms of actions
of CBD that could inhibit the death of neurons out of
knowledge about the cytotoxic mechanisms determined by a
number of experimental studies and the present results from
molecular modeling.
For the possible inhibition of cytotoxicity in systems with
Aβ(31−35) CBD could bind to MET35, alter the peptide
secondary structure, and adsorb Aβ(31−35) on CBD clusters.
In the case of Aβ(25−35) the suppression of peptide
aggregation can be an additional action of CBD against the
Aβ cytotoxicity, while for Aβ(31−35) peptide aggregation
might not be relevant at all. All those mechanisms are
interdependent as well: inhibited aggregation can be due to
altered secondary structures. The adsorption on CBD clusters
can occur through binding to MET35.
Moreover, the amount of water in the simulated mixtures
also plays a role in the peptide aggregation process as well as in
the interactions between peptides and CBD molecules. Both
peptides show a higher tendency to aggregate in the absence of
the drug in the systems with the lower water content. The
presence of CBD can, however, promote peptide aggregation
around CBD clusters in the water rich systems. Additionally,
the number of hydrogen bonds detected between peptides and
water was higher in the systems with Aβ(25−35) than with
Aβ(31−35). The presence of the drug molecules did not affect
the number of hydrogen bonds in the simulated systems.
From computational results we can say that CBD shall be
considered for further in vivo and in vitro studies as a possible
drug against the neurodegenerative diseases. As future in silico
experiments, MD simulations of mixtures with various ratios of
CBD and peptides, including Aβ peptides with longer chains,
should be considered. Moreover, combining computational
and experimental studies would help to find optimal
concentrations of the drug.
■ METHODS
Classical MD Simulations. Before the setting up of MD
simulations, the model for the CBD molecule was derived using the
same approach as for the general Amber force field (GAFF).83
Twenty random conformations were utilized for the calculations of
partial atomic charges. According to the specification of GAFF, the
partial atomic charges were computed on the optimized molecular
geometries by ab initio calculations employing the Hartree−Fock
method with the 6-31G(d) basis set and the restrained electrostatic
potential (RESP)84 fitting method. Gaussian 1685 was used for those
computations.
After the derivation of the CBD model, starting configurations for
MD were set up. Compositions of simulated systems are shown in
Table 2. First, systems 1−4 were created in the following way: in
order to avoid clustering, the peptides were placed in empty boxes
with an artificial van der Waals radius equal to 0.5 nm. Then in
configurations with Aβ(25−35) chlorine counterions were added to
compensate the positive charge of the peptide (one ion per one
Aβ(25−35)). Aβ(31−35) had a total charge equal to 0 so no
counterions were inserted in simulations with this peptide. Systems 5
and 6 with CBD were built applying the same van der Waals distance
of 0.5 nm around every CBD molecule. Systems 7−10 were created
from the starting configurations 1−4 by adding the CBD molecules
using the van der Waals radii of 0.5 nm around each molecule.
Table 2. Molecular Compositions of Simulated Systems
system number of Na ions number of water molecules
6 Aβ(25−35) 6 10000
6 Aβ(31−35) 0 10000
8 Aβ(25−35) 8 10000
6 Aβ(31−35) 0 10000
6 CBD 0 10000
8 CBD 0 10000
6 Aβ(25−35) + 6 CBD 6 10000
6 Aβ(31−35) + 6 CBD 0 10000
8 Aβ(25−35) + 8 CBD 8 10000
8 Aβ(31−35) + 8 CBD 0 10000
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://dx.doi.org/10.1021/acschemneuro.0c00692
ACS Chem. Neurosci. 2021, 12, 660−674
670
Chlorine counterions were added in every simulation box containing
Aβ(25−35) for compensating the positive charge. After the insertion
of larger molecules and ions the water molecules were randomly
placed in every system.
The models for the Aβ peptides were taken from amber99sb-ildn
FF86 at neutral pH. All systems were simulated for 250 ns in the NPT
ensemble using the isotropic pressure coupling scheme, where the
equilibration was 10 ns long. The temperature of 310 K was regulated
by a Velocity Rescale thermostat87 with a coupling constant of 0.5 ps.
The pressure of 1 atm was retained by the Berendsen barostat88 with a
coupling constant of 10 ps and a compressibility of 0.000 045 bar−1.
All bonds were constrained by using the LINCS89,90 algorithm with
12 iterations. The time step was 2 fs and the cutoff value was 0.9 nm.
The integrator was the leapfrog algorithm.91 The MD software was
GROMACS 2019.92,93 Final dimensions of simulation boxes after
equilibration with classical MD simulations are shown in Table S1 of
Supporting Information.
Well-Tempered Metadynamics Simulations. Well-tempered
metadynamics simulations were carried out for 6 systems.
The first 2 systems contained only 2 peptides each (one with 2
Aβ(25−35) and another one with 2 Aβ(31−35)), where the
collective variable (CV) was the distance between the center of
mass of the peptides (Figure 9a). These simulations were 7 μs long.
The second 2 systems contained 2 peptides each and 1 CBD
molecule each. Two collective variables were given by the distance
between the center of mass of the peptides (CV1) and the distance
between the center of mass of the CBD molecule and one of the
peptides (CV2) (Figure 9b). During these simulations the distance
between the center of mass of the second peptide and the CBD
molecule was not taken into account. These simulations were 10 μs
long.
The final 2 systems contained 2 peptides and 2 CBD molecules
each. Two collective variables were given by the distance between the
center of mass of the peptides (CV1) and the distance between the
center of mass of one of the CBD molecules and one of the peptides
(CV2) (Figure 9c). During these simulations the following distances
were not considered: the distance between the center of mass of the
first peptide and the second CBD molecule, the distance between the
center of mass of the second peptide and the first CBD molecule, the
distance between the center of mass of the second peptide and the
second CBD molecule, and the distance between the center of mass of
the two CBD molecules. These simulations were 12 μs long.
Starting configurations were created in the following way: two
simulation boxes containing peptides and CBD molecules were
selected from classical MD simulations. One box was with 6 Aβ(25−
35) and 6 CBD molecules, and another box was with 6 Aβ(31−35)
and 6 CBD molecules. For the well-tempered metadynamics
simulations with 2 peptides in the selected 2 boxes only 2 peptides
and water molecules (and counterions for Aβ(25−35)) were kept.
Then the 2 resulting boxes were equilibrated for 10 ns in the NPT
ensemble at a pressure of 1 atm and a temperature of 310 K. Final
frames were used for well-tempered metadynamics simulations. All
other starting configurations for simulations containing 2 peptides and
1−2 CBD molecules were created using a similar approach from the
same frames, extracted from classical MD simulations. The number of
water molecules was kept the same as in the classical MD simulations.
Final dimensions of the simulation boxes after equilibration with
classical MD simulations are demonstrated in Table S2 of Supporting
Information.
After preparation of the starting configurations, parameters for well-
tempered metadynamics simulations were set. The Gaussian functions
of the height 1.2 kJ/mol and the width for every collective variable of
0.05 nm (the parameter σ) were deposited every 500 steps (i.e., the
parameter PACE was 500). The bias factor, γ, was equal to 50.0. The
simulations were carried out in the NVT ensemble by the Velocity
Rescale87 thermostat at a temperature of 310 K using GROMACS
2019.492,93 as an MD engine with PLUMED 2.5.494 for well-tempered
metadynamics. The employed force fields were the same as the ones
used for the classical MD simulations. The time step was 2 fs, the
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CV2 is the distance between centers of mass of a peptide and a CBD
molecule. The black arrow shows the distance which was not taken
into account. (c) 2D simulations for systems containing 2 peptides
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